# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Janux Therapeutics (NASDAQ:JANX) with a Buy and raises the ...
Cantor Fitzgerald analyst Josh Schimmer reiterates Janux Therapeutics (NASDAQ:JANX) with a Overweight and maintains $100 pri...
Wedbush analyst Robert Driscoll maintains Janux Therapeutics (NASDAQ:JANX) with a Outperform and raises the price target fro...
- Sec Filing
Janux Therapeutics (NASDAQ:JANX) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(...
JonesTrading analyst Soumit Roy initiates coverage on Janux Therapeutics (NASDAQ:JANX) with a Buy rating and announces Price...
Shares of Fastenal Company (NASDAQ: FAST) fell sharply during Thursday’s session following worse-than-expected first-quarter f...